e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
State of the art session: Thoracic oncology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies
N. Girard (Paris, France)
Source:
International Congress 2019 – State of the art session: Thoracic oncology
Session:
State of the art session: Thoracic oncology
Session type:
Symposium
Number:
4890
Disease area:
-
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Girard (Paris, France). Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies. International Congress 2019 – State of the art session: Thoracic oncology
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Definition and history of sarcoidosis
Related content which might interest you:
Current challenges in the management of nonsmall cell lung cancer brain metastases
Source: Eur Respir J, 55 (1) 1901686; 10.1183/13993003.01686-2019
Year: 2020
Possibilities of palliative combined therapy for extensive nonsmall cells lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 378s
Year: 2001
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
Source: Eur Respir Rev 2014; 23: 79-91
Year: 2014
Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm
Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019
Year: 2020
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer
Source: Eur Respir J 2013; 42: 1119-1133
Year: 2013
New and anticipated therapeutic developments in management of non-small-cell lung cancer
Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer
Year: 2013
Targeted therapy in non-small cell lung cancer
Source: Breathe 2012; 8: 206-215
Year: 2012
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
Source: Eur Respir Rev 2011; 20: 45-52
Year: 2011
Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service
Source: International Congress 2018 – Genetics in chronic pulmonary diseases
Year: 2018
Biological therapies in nonsmall cell lung cancer
Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016
Year: 2017
The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches
Source: Virtual Congress 2021 – Thoracic oncology
Year: 2021
Second-line combination therapies in nonsmall cell lung cancer without known driver mutations
Source: Eur Respir Rev 2015; 24: 582-593
Year: 2015
Towards personalized treatment in non-small-cell lung carcinoma
Source: Virtual Congress 2020 – Management issues in thoracic oncology
Year: 2020
Anticancer treatment for advanced non-small cell lung cancer
Source: Breathe 2011; 8: 124-133
Year: 2011
Impacts of multi and specific co-morbidities on the survival of non-surgical non-small cell lung cancer
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations
Source: Eur Respir J 2015; 46: 19-21
Year: 2015
Innovative local therapies in lung cancer
Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy
Year: 2018
Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
Source: Eur Respir J, 52 (6) 1801100; 10.1183/13993003.01100-2018
Year: 2018
Advances in target therapy in lung cancer
Source: Eur Respir Rev 2015; 24: 23-29
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept